No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US Stock MarketDetailed Quotes
FATE Fate Therapeutics
- 1.680
- +0.020+1.20%
Close Dec 20 16:00 ET
- 1.680
- +0.000+0.01%
Post 19:28 ET
191.34MMarket Cap-1.02P/E (TTM)
1.800High1.640Low10.14MVolume1.675Open1.660Pre Close17.11MTurnover10.23%Turnover RatioLossP/E (Static)113.89MShares8.83052wk High0.53P/B166.54MFloat Cap1.59052wk Low--Dividend TTM99.13MShs Float121.160Historical High--Div YieldTTM9.61%Amplitude1.460Historical Low1.688Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Barclays Maintains Fate Therapeutics(FATE.US) With Buy Rating, Maintains Target Price $10
BofA Securities Maintains Fate Therapeutics(FATE.US) With Hold Rating, Maintains Target Price $3
Hold Rating for Fate Therapeutics Amid Incremental Progress in CD19 CAR-T Therapy Development
Fate Therapeutics Reports FT819 Shows 'Favorable Safety Profile,' Clinical Benefits
Express News | Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 off-the-Shelf, Car T-Cell Product Candidate for Systemic Lupus Erythematosus
TD Cowen Maintains Fate Therapeutics(FATE.US) With Hold Rating
Heat List
US
Overall
Symbol
Price
% Chg
No Data